Repositioning Candidate Details
| Candidate ID: | R0240 |
| Source ID: | DB00841 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Dobutamine |
| Synonyms: | |
| Molecular Formula: | C18H23NO3 |
| SMILES: | CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1 |
| Structure: |
|
| DrugBank Description: | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. |
| CAS Number: | 34368-04-2 |
| Molecular Weight: | 301.3801 |
| DrugBank Indication: | Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. |
| DrugBank Pharmacology: | Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with negligible effects on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. |
| DrugBank MoA: | Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. |
| Targets: | Alpha-1 adrenergic receptors; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Estrogen receptor alpha |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|